The duration of pituitary suppression by means of intranasal gonadotropin hormone-releasing hormone analogue administration does not influence the ovarian response to gonadotropin stimulation and success rate in a gamete intrafallopian transfer (GIFT) program

• Published in: Journal of in vitro fertilization and embryo transfer Vol. 6; no. 2; p. 76
• Main Authors: Remorgida, V, Anserini, P, Croce, S, Costa, M, Ferraiolo, A, Centonze, A, Gaggero, G, Capitanio, G L
• Format: Journal Article
• Language: English
• Published: United States 01.04.1989
• Subjects: Administration, Intranasal; Adult; Buserelin - pharmacology; Drug Administration Schedule; Female; Gamete Intrafallopian Transfer; Gonadotropins - pharmacology; Humans; Hypophysectomy, Chemical; Male; Menstrual Cycle; Middle Aged; Ovary - drug effects; Pituitary Gland - drug effects; Time Factors
• ISSN: 0740-7769
• DOI: 10.1007/BF01130730

The aim of the study was to compare the ability to prevent endogenous luteinizing hormone interferences, ovarian response, and success rate between two groups of patients undergoing GIFT procedures and treated with the same stimulatory protocol but with a different timing in the administration of the gonadotropin hormone-releasing hormone analogue (GnRH-a). The former underwent a concomitant administration of gonadotropin and analogue; the latter started stimulation only after the achievement of complete hypogonadotropinism. The analogue was always given intranasally and stimulation was identical in the two groups. Our results showed that (1) prevention of premature luteinization is obtained with both approaches and (2) no significant difference in terms of length of stimulation, gonadotropin doses, ovarian response, and success rate was recorded between the two groups.